William Blair reissued their outperform rating on shares of Aduro Biotech, Inc. (NASDAQ:ADRO) in a research note issued to investors on Monday morning.

Several other brokerages have also recently weighed in on ADRO. HC Wainwright reiterated a buy rating and set a $18.00 price target on shares of Aduro Biotech in a research report on Wednesday, September 27th. BidaskClub cut Aduro Biotech from a hold rating to a sell rating in a research report on Tuesday, August 8th. Canaccord Genuity set a $30.00 price objective on Aduro Biotech and gave the company a buy rating in a research report on Thursday, August 3rd. Zacks Investment Research cut Aduro Biotech from a buy rating to a hold rating in a research report on Wednesday, August 2nd. Finally, Cowen and Company began coverage on Aduro Biotech in a research note on Tuesday, July 18th. They issued an outperform rating on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $19.00.

Aduro Biotech (NASDAQ:ADRO) opened at 10.75 on Monday. Aduro Biotech has a 52-week low of $8.75 and a 52-week high of $15.52. The stock has a 50 day moving average price of $11.16 and a 200 day moving average price of $10.94. The stock’s market cap is $802.08 million.

Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The business had revenue of $5.90 million during the quarter, compared to analyst estimates of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. Aduro Biotech’s revenue was down 84.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.03 EPS. Analysts expect that Aduro Biotech will post ($1.35) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Aduro Biotech, Inc. (ADRO) Given Outperform Rating at William Blair” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.dailypolitical.com/2017/10/05/aduro-biotech-inc-adro-given-outperform-rating-at-william-blair.html.

In other Aduro Biotech news, insider Thomas W. Dubensky sold 50,000 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $11.38, for a total transaction of $569,000.00. Following the completion of the sale, the insider now directly owns 80,812 shares of the company’s stock, valued at approximately $919,640.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Gregory W. Schafer sold 40,000 shares of the stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $12.17, for a total value of $486,800.00. Following the sale, the chief operating officer now directly owns 133,879 shares of the company’s stock, valued at $1,629,307.43. The disclosure for this sale can be found here. Over the last three months, insiders sold 342,745 shares of company stock valued at $3,956,397. Insiders own 6.60% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc raised its stake in shares of Aduro Biotech by 11.2% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after buying an additional 1,043 shares in the last quarter. Tudor Investment Corp ET AL increased its stake in Aduro Biotech by 34.8% in the 1st quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 3,984 shares in the last quarter. Parametric Portfolio Associates LLC increased its stake in Aduro Biotech by 15.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 2,119 shares in the last quarter. Voya Investment Management LLC increased its stake in Aduro Biotech by 15.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock valued at $216,000 after purchasing an additional 2,515 shares in the last quarter. Finally, American International Group Inc. increased its stake in Aduro Biotech by 7.1% in the 1st quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock valued at $235,000 after purchasing an additional 1,447 shares in the last quarter. 35.05% of the stock is owned by institutional investors.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Analyst Recommendations for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.